Defining what happens to replication machineries when they are blocked is highly relevant. Indeed, 56 destabilised replication machineries may form upon treatment with anticancer drugs and influence 57 the efficacy of some of them in specific genetic backgrounds. We used cells that lack one of the two 
INTRODUCTION

72
The response to perturbed replication is crucial for the maintenance of genome integrity [1] [2] [3] [4] [5] . In forks undergoing pathological degradation but in a BRCA2-RAD51 wild-type background.
101
Here, we report that, upon prolonged exposure to nanomolar dose of CPT, loss of WRN exonuclease 102 channels replication forks through a pathological RAD51-dependent mechanism that makes 103 perturbed replication forks resistant to breakage. However, engagement of RAD51 and persisting We first examined the presence of nascent ssDNA as a sign of fork degradation by the native IdU 121 assay. As expected, WS cells expressing the exo-dead WRN protein (WS E84A ) showed less nascent 122 ssDNA then the corrected wild-type counterpart (WS WT ) at 1h of treatment (Fig. 1A) . Surprisingly, MRE11, barely reduced ssDNA detected at 4h of treatment in wild-type cells (Fig. 1B) . Surprisingly,
130
Mirin did not decrease the formation of ssDNA in WRN exonuclease-deficient cells but rather 131 increased it even further (Fig. 1B) . Inhibition of DNA2 by the small-molecule inhibitor C5 [20] 132 increased formation of nascent ssDNA in wild-type but not in WRN exonuclease-deficient cells (Fig.   133 1B). In contrast, concomitant inhibition of DNA2 and MRE11 was ineffective in modulating nascent 134 ssDNA formation in wild-type cells while decreased its level in cells expressing the exo-dead form 135 of WRN (Fig. 1B) . Of note, ssDNA derived from end-resection of DSBs induced by a micromolar 136 dose of CPT was efficiently reduced by DNA2 inhibitor C5 (Fig. S1A, B treatment with nanomolar CPT by neutral Comet assay. As shown in Figure 1C , treatment with 50nM
145
CPT for 4h is able to induce some DSBs in wild-type cells, although they are very low compared with 146 those generated by the 5µM reference dose. In contrast, no DSBs were detected in WRN exonuclease-147 deficient cells after treatment with the low-dose of CPT, even if they were readily seen in response 148 to the high-dose of the drug (Fig. 1C) . Interestingly, pre-treatment with Mirin, which enhances 149 ssDNA in WS E84A cells (Fig. 1B) , resulted in DSBs (Fig. 1C) . In contrast, formation of DSBs was 150 unaffected in wild-type cells by Mirin while it was reduced by the DNA2 inhibitor (Fig. 1C) .
151
Interestingly, inhibition of both MRE11 and DNA2, which decreases ssDNA formation in WS E84A 152 cells (Fig. 1B) , reduced significantly the DSBs generated by Mirin (Fig. 1C) . Concomitant inhibition 153 of MRE11 and DNA2 also reduced DSBs in wild-type cells (Fig. 1C) To evaluate recruitment of RAD51, we first prepared chromatin from cells treated with nanomolar
175
CPT and determined the amount of RAD51 present by Western blotting. In wild-type cells, RAD51 176 barely increased its chromatin association after CPT treatment ( Fig. 2A) . Expression of the exo-dead 177 WRN, however, greatly increased the amount of RAD51 in chromatin both in untreated cells and that binds to ssDNA, in chromatin. RPA32 increased after CPT in wild-type cells ( Fig. 2A) . In 181 contrast, the amount of RPA32 in chromatin was low in the absence of the WRN exonuclease and 182 did not show any increase after treatment ( Fig. 2A) immunofluorescence analysis of the RAD51 foci (Fig. 2B) . We evaluated the number of foci by 186 analysing the intensity of fluorescence in the RAD51 foci-positive nuclei. Consistent with 187 biochemical data, loss of WRN exonuclease increased recruitment of RAD51 (Fig. 2B) . Moreover,
188
CPT treatment led to a higher number of RAD51 foci in WRN exonuclease-deficient cells compared 189 with the wild-type (Fig. 2B) 
190
These results suggest that, in the absence of the WRN exonuclease, RAD51 takes over the normal during recovery from CPT in wild-type cells (Fig. 3B) . In contrast, the number of RAD51 foci 204 increased in WRN exonuclease-deficient cells (Fig. 3B ), confirming that a RAD51-dependent 205 pathway is over-activated in response to prolonged treatment with low-dose of CPT in these cells. foci was elevated in WRN exonuclease-deficient cells after treatment and even more during recovery 213 (Fig. 3C) . Interestingly, concomitant pre-treatment with C5 and Mirin significantly reduced the 214 formation of RAD51 foci in WS E84A cells (Fig. 3C) CPT and perform recovery (Fig. 3D ). As shown in Figure 3E , little parental ssDNA was detectable 223 in wild-type cells after treatment and its amount decreased substantially during recovery. In WS E84A 224 cells, however, parental ssDNA was higher at the end of treatment and remained elevated during 225 recovery (Fig. 3E) . Interestingly, the increased amount of parental ssDNA paralleled that of RAD51 226 foci, suggesting that RAD51 may be recruited to deal with under-replicated regions. limited new origin firing was detectable in wild-type cells (Fig. 4C, D) . Surprisingly, and in spite of 
247
These results suggest that RAD51 is not required to promote replication recovery but rather to (Fig. 1A) , we analysed the presence of TopBP1 and RAD9, which associates with TopBP1
277
[26,27], specifically at nascent ssDNA by our recently described IdU-PLA assay [11] . In parallel, we (Fig. 5D, E) . Of note, loss of WRN exonuclease reduced the recruitment of TopBP1 but 282 not that of RAD9 at the nascent ssDNA (Fig. 5D , E) although in these conditions the IdU assay 283 detected 2-times more ssDNA (Fig. 5F ). to low-dose of CPT (Fig. 7A) . In contrast, many pS87-MUS81-positive nuclei were detectable in 314 cells expressing the exonuclease-dead WRN already in unperturbed conditions (Fig. 7A) . Notably, in 315 WRN exonuclease-deficient cells, pS87-MUS81 levels were further enhanced by CPT and remained 316 elevated also after recovery (Fig. 7A) . Interestingly, and consistent with our previous results [32], 317 phosphorylation of MUS81 never occurred in S-phase cells labelled with EdU (Fig. 7A) . To defects, we first analysed the presence of bulky anaphase bridges in DAPI-stained cells (Fig. 7C) . (Fig. 7D) . Figure 7E , the number 344 of 53BP1 NBs in WS E84A cells was higher than in wild-type cells even in untreated conditions.
345
Treatment with CPT enhanced the number of 53BP1 NBs in wild-type and in WRN exonuclease-13 346 deficient cells; however, the increase was substantially higher in cells expressing the exo-dead WRN 347 ( Fig. 7E and Fig. S5 ). the number of multinucleated cells (Fig. 8A) . In sharp contrast, expression of the S87A-MUS81 360 mutant substantially aggravated the mitotic defects in WRN exonuclease-deficient cells (Fig. 7A) . 
370
In contrast, overexpression of the S87A-MUS81 resulted in a substantial increase in the sensitivity of 371 WRN exonuclease-deficient cells to CPT (Fig. 8C) . of those forks that failed to be processed otherwise [13] . Loss of the ability to induce DSBs at forks [11], which is required to avoid unscheduled RECQ1 activation [13] , which, together with the absence 408 of DSBs support a pathway switch at CPT-perturbed forks. 
533
Only nuclei with > 5 foci were considered as positive and were quantified using ImageJ.
535
EdU incorporation assay
536
To label replicated DNA, cells were incubated with 10 µM EdU for 30 minutes. Samples were fixed 537 with 4% PFA at RT for 10 min and cells were subsequently permeabilized with 0,5% Triton-X100. 
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Statistical analysis was performed by the Mann-Whitney test (**P < 0.1; ****P < 0.001).
812
Representative images are shown. Nascent strand was labelled with IdU for 15min before cells were treated with 50nM CPT for 4h.
838
PLA was performed under native conditions using anti-IdU to detect nascent ssDNA and anti- 
